MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC

J Thorac Oncol. 2019 Jul;14(7):e148-e151. doi: 10.1016/j.jtho.2019.02.030.

Authors

Wenfeng Fang¹, Jiadi Gan¹, Shaodong Hong¹, Feng Lu², Li Zhang³

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
² Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
³ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: [email protected].

PMID: 31235041
DOI: 10.1016/j.jtho.2019.02.030

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adaptor Proteins, Signal Transducing / genetics*
Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / pathology
Adult
Anaplastic Lymphoma Kinase / genetics*
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Gene Rearrangement*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Oncogene Proteins, Fusion / genetics*
Pemetrexed / administration & dosage
Prognosis

Substances

Adaptor Proteins, Signal Transducing
Antibodies, Monoclonal, Humanized
MPRIP protein, human
Oncogene Proteins, Fusion
Pemetrexed
pembrolizumab
ALK protein, human
Anaplastic Lymphoma Kinase